linjc16/ctgov huggingface dataset:
Fundamental Movement Skills, Body Mass Index and Quality of Life in Children

Study Overview
=================
Brief Summary
-----------------
Early childhood obesity is a serious worldwide problem, and fundamental movement skills (FMS) are very important factors in human movement. Thus, several advanced studies have examined the associations between FMS, body mass index (BMI) and quality of life. The purpose of this study was to investigate the relation between FMS, BMI and quality of life in Egyptian school aged children.

Detailed Description
-----------------
A total of 216 primary school aged children, aged 5-7 y from both sex participated in this study. FMS were measured using the Test of Gross Motor Development-II (TGMD-II), and BMI was calculated as the weight (kg) divided by the square of the height (m) [weight/ height2] ,and quality of life was measured by PedsQol scale

Official Title
-----------------
Correlation Between Fundamental Movement Skills, Body Mass Index, and Quality of Life in School Aged Children

Conditions
-----------------
Overweight Children

Intervention / Treatment
-----------------
* Other: fundamental movement skills


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - normal school aged children , aged 5-7 years with different weight categories Exclusion Criteria: children with visual or auditory problems or those who experienced surgery in their lower limbs 1 year before study

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: fundamental movement skills|measured by test of gross motor development|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| test of gross motor development | a valid and reliable test for assessing fundamental movement skills in children aged 3-10 years | 3 months | 
| body mass index | used to assess anthropometric measurements | 3 months | 
| PedsQol scale | used to assess quality of life in children. generic core scale will be used and total score will be used in analysis | 3 months |
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

Study Overview
=================
Brief Summary
-----------------
Bevacizumab is widely prescribed for the treatment of severe bleeding related to epistaxis or gastrointestinal bleeding in HHT. We studied the efficacy of bevacizumab on severe bleeding in HHT patients in a randomized study recently published (NCT03227263, J Int Med 2023). In this study, 24 patients were included, 12 patients received bevacizumab and 12 patients received placebo. The duration of patient participation was 6 months, including the 2.5-month treatment period and 3.5 month follow-up after treatment. We describe the evolution of the number of RBC transfused in HHT patients who received bevacizumab during the year after the end of the study.

Official Title
-----------------
Subsequent Bevacizumab Treatment in Patients With HHT After the End of BABH Interventional Study. A Descriptive Study.

Conditions
-----------------
Hemorrhagic Hereditary Telangiectasia, HHT

Intervention / Treatment
-----------------
* Other: bevacizumab treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient included in BABH study Exclusion Criteria: Patients opposition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HHT patients previously included in BABH study<br>Clinical and therapeutic follow-up of HHT patients for one year after the end of a clinical trial using bevacizumab. | Other: bevacizumab treatment<br>* Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bevacizumab treatment description after end of BABH study | Number of patients who received bevacizumab after BABH study. Among patients who received bevacizumab in BABH study: description of re-treatments. In patients who received placebo in BABH study: description of treatments. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HHT, VEGF therapy, BEVACIZUMAB
The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

Study Overview
=================
Brief Summary
-----------------
A monocentric prospective study was conducted to find the relevance between the level of fetal hemoglobin and short-term complications in extremely preterm infants

Official Title
-----------------
The Relevance Between the Level of Fetal Hemoglobin and Short-term Complications in Extremely Preterm Infants

Conditions
-----------------
Fetal Hemoglobin

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preterm infants with gestational age <32 weeks or birth weight <1500g Parents agree to attend Exclusion Criteria: serious functional or organic diseases severe congenital deformity parents reject to attend

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group<br>Incorporate blood gas analysis indicators in D1-D7, after birth,1 week before and on the day of onset of early complications | |
| Control group<br>Incorporate blood gas analysis indicators in D1-D7,D14,D28after birth and the day of diacharge | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence and severity of early complications in premature infants | include necrotizing enterocolitis,bronchopulmonary dysplasia,retinopathy, Intraventricular hemorrhage above degree Ⅱ,leukomalacia,late-onset sepsis | 2022.1-2023.1 |
A Home Telemonitoring System for Wearable Fetal-ECG and EHG Acquisition During Pregnancy

Study Overview
=================
Brief Summary
-----------------
The goal of this observational is to compare in describing fetal health conditions. The main questions it aims to answer are: fetal electrocardiogram (fetal heart rate and fetal rhythm) electrohysterography (uterine contractions). Participants will wear wearable devices and CTG equipment for monitoring for 30 minutes.If there is a comparison group: Researchers will compare clinical CTG equipment to see if this wearable device.

Detailed Description
-----------------
The investigators put the patch of the wearable device on the abdomen of the pregnant woman and continued the test for thirty minutes.

Official Title
-----------------
Flexible Wearable Device for Continuous Fetal Heart Rate and Movement Monitoring.

Conditions
-----------------
Uterine Contractions; Prolonged, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus, Pregnancy Related, Home Range

Intervention / Treatment
-----------------
* Device: use wearable devices to monitoring fetal health conditions.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with a gestational cycle greater than 36 weeks Exclusion Criteria: male Pregnant women with a gestational cycle less than 36 weeks
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: use wearable devices to monitoring fetal health conditions.|We used wearable devices and clinical cardiotocography (CTG) equipment to monitor pregnant women for 30 minutes to demonstrate the reliability of wearable devices.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The performance of this system in extracting fetal electrocardiogram (FECG) | extract fetal QRS intervals and numbers from FECG | 2022.01-2023.08 | 
| The performance of this system in extracting electrohysterography (EHG) | use the contractions consistency index (CCI) parameters to analyze the relation between our measured EHG signal and the UC signal recorded by clinical CTG equipment. | 2022.01-2023.08 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FECG, EHG
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Study Overview
=================
Brief Summary
-----------------
The goal of this cross-sectional study is to evaluate epigenetic modifications in gastric carcinogenesis, mainly in H. pylori gastritis vs gastric carcinoma. The main question[s] it aims to answer are: How does H. pylori infection cause gastric cancer? Can DNA methylation and other epigenetic changes predict and affect the development of gastric cancer? Formalin-fixed-paraffin-embedded tissue specimens will be obtained and reviewed for comparison between epigenetic changes in H. pylori gastritis and gastric adenocarcinoma.

Official Title
-----------------
Immunohistochemical Evaluation of DNA Methylation and Histone Modification in H. Pylori Associated Gastric Carcinoma

Conditions
-----------------
Gastric Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: Immunohistochemical staining for DNMT1 and EZH2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Resected specimens and endoscopic guided biopsies of intestinal type gastric carcinoma, H. Pylori associated gastritis, and non-H. Pylori gastritis with: Available full clinical data: (age, sex, complaint, findings in clinical examination). Full data of previous endoscopy and radiology. Exclusion Criteria: Cases of diffuse type gastric carcinoma. Any case of gastric cancer, H. Pylori associated gastritis, non-H. Pylori gastritis, benign gastric lesions with missing clinical, endoscopic, radiologic or follow-up data. Cases with no available H&E stained slides or formalin fixed paraffin embedded block.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| H. pylori Gastritis specimens<br> | Diagnostic Test: Immunohistochemical staining for DNMT1 and EZH2<br>* Immunohistochemical staining for DNMT1 and EZH2 using rabbit monoclonal/polycolonal antibodies with immunoperoxidase staining will be used as a visualization method. Antibodies dilutions, antigen retrieval methods, and incubation time will all be conducted according to the manufacturer's instructions.<br>|
| Non-H. pylori Gastritis specimens<br> | |
| Gastric carcinoma specimens<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in DNMT1 and EZH2 expression. | Histopathological evaluation of routine H&E slides and immunohistochemical markers to compare the intensity and extent of epigenetic changes in both H. Pylori associated gastritis and gastric carcinoma. | two years |
Corrective Osteotomy of the Distal Radius Without Bone Grafting

Study Overview
=================
Brief Summary
-----------------
The investigators retrospectively analyzed patients who underwent extraarticular corrective osteotomy of the distal radius via a palmar approach and without the use of a bone graft, even in the absence of cortical contact after corrective osteotomy. The goal of this retrospective observational study is to determine whether secondary dislocation or nonunion occurs after corrective osteotomy without bone grafting.

Official Title
-----------------
Corrective Osteotomy of the Distal Radius With Palmar Locking Plate Osteosynthesis Without Bone Grafting and Without Cortical Contact

Conditions
-----------------
Distal Radius Fracture

Intervention / Treatment
-----------------
* Procedure: Corrective osteotomy of the distal radius


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: malunited distal radius fracture extraarticular corrective osteotomy palmar approach no bone graft used no cortical contact after dorsal open wedge osteotomy signed informed consent Exclusion Criteria: others reasons for malunion intraarticular corrective osteotomy use of a bone graft cortical contact after open wedge osteotomy lost to follow up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Corrective osteotomy of the distal radius|Corrective osteotomy of the distal radius with a palmar locking plate osteosynthesis without the use of a bone graft and without cortical contact.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Secondary fracture dislocation |  | 1 year | 
| complete bone healing |  | 1 year |
Expanded Access for Repotrectinib

Study Overview
=================
Brief Summary
-----------------
This is an expanded access designed to provide access to Repotrectinib for eligible participants.

Intervention / Treatment
-----------------
* Drug: Repotrectinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Exclusion Criteria: -

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Repotrectinib|Repotrectinib|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
System Accuracy of 14 Blood Glucose Monitoring Systems

Study Overview
=================
Brief Summary
-----------------
The system accuracy of 14 blood glucose monitoring systems is to be evaluated randomly in accordance with DIN EN ISO 15197:2015 over thr courese of 24 months

Official Title
-----------------
Leistungsbewertungsprüfung Der Systemgenauigkeit, Von 14 Blutglukose Monitoring Systemen in Anlehnung an ISO 15197:2015

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Diagnostic Test: Glucometer Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Male or female patients with hypo-, eu- or hyperglycaemia The written informed consent had to be signed The volunteers must be older than 18 years The volunteers have legal capacity and are able to understand meaning, nature and possible consequences of the procedures involved Exclusion criteria: Pregnancy or lactation Acute or chronic diseases with the risk of aggravation by the measure A current constitution that does not allow participating in the study Participation in another study or activity with the blood glucose measuring system evaluated in the present study Application of substances listed in Appendix A of DIN EN ISO 15197:2015

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Subject glucometer measurement<br> | Diagnostic Test: Glucometer Test<br>* measurement of blood glucose concentration using different BGM and Reference Method<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood glucose measurement using BGMS |  | Day 1 |
Healthy Thai Project With Bangkoknoi Model: Fatless Community

Study Overview
=================
Brief Summary
-----------------
The goal of this interventional study is to make people in a community realize negative effects of obesity on health, and how to tackle it by adopting a lifestyle modification for weight reduction. Adults aged 20 years old or more with obesity (BMI ≥ 25 kg/m2) or waist circumference ≥ 80 cm in women and ≥ 90 cm in men were recruited. All participants received an educational session of lifestyle modification for weight reduction on the first day of study. Participants were then assigned to either continuously receive education (video clips and infographics) via application LINE, or no further education. The main questions it aims to answer are: Whether or not an educational session of lifestyle modification leads to weight reduction. Whether or not a weight loss by a continuous education via an online application is more effective than not receiving it.

Official Title
-----------------
Healthy Thai Project With Bangkoknoi Model: Fatless Community

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: application LINE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obesity (BMI ≥ 25 kg/m2) Waist circumference ≥ 80 cm in women and ≥ 90 cm in men Exclusion Criteria: Contraindications for bioelectrical impedance analysis Active cancer No available health data

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Study group<br>Continuously receiving education (video clips and infographics) via application LINE | Behavioral: application LINE<br>* Online lifestyle modification education for weight loss<br>|
| No Intervention: Control group<br>No application LINE | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight change | Body weight change | 6 months after intervention |
Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.

Official Title
-----------------
An Investigator-Initiated Open-Label, Multiple-Dose Clinical Study to Evaluate the Safety,Tolerability, and Efficacy of Gene Therapy for 2Leber's Congenital Amaurosis With RPE65 Mutation (LCA2)

Conditions
-----------------
Leber Congenital Amaurosis

Intervention / Treatment
-----------------
* Genetic: HG004


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or females between 8 and 50 years of age at the time of signing theinformed consent form. Willing to adhere to protocol as evidenced by written informed consent orparental permission and subject assent. Clinical confirmed diagnosis of Leber congenital amaurosis (LCA) andmolecular diagnosis of LCA due to RPE65 mutations. Ability to perform tests of visual and retinal function. Visual acuity of ≤ 20/160 or visual field less than 20 degrees in the eye to beinjected. Acceptable hematology, clinical chemistry, and urine laboratory parameters. Exclusion Criteria: OCT examination determined that the outer nuclear layer was not visible inthe planned injection area (Bleb) in the study eye. Presence of epiretinal membrane by OCT. Complicating systemic diseases or clinically significant abnormal baselinelaboratory values. Complicating systemic diseases would include those in which the diseaseitself, or the treatment for the disease, can alter ocular function. Prior ocular surgery within six months. Prior gene therapy or oligonucleotide therapy treatments. Any other condition that would not allow the potential subject to completefollow-up examinations during the study and would, in the opinion of theinvestigator, make the potential subject unsuitable for the study.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HG004<br> | Genetic: HG004<br>* Method of Administration: Once unilateralsubretinal injection; The duration of the study isabout 60 weeks for each subject including a 8-weekscreening period, enrollment/baseline visit,treatment visit, and 52 weeks follow-up period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence and severity of ocular and systemic adverse events | Number of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) | 26 weeks |